Manipal Health Enterprises IPO: Should You Apply, Wait, or Watch for the Listing Dip?
.webp)
Key Takeaways
- Manipal Health Enterprises IPO is priced at ₹560-₹590 with an issue size of 15,72,07,054 shares.
- GMP stands at ₹15 (2.54%), signaling modest demand ahead of listing.
- Key concerns include high borrowings and a YoY decline in PAT despite revenue growth.
- Retail investors should decide to apply, avoid, or watchlist based on risk tolerance and final price discovery.
Business &Amp Promoter Background
Manipal Health Enterprises Limited is a main-board IPO comprising equity shares with a face value of ₹2 each. The issue structure includes a fresh issue of 13,55,93,220 shares aggregating up to ₹8,000 crore and an OFS of 2,16,13,834 shares aggregating up to ₹1,275 crore. The company operates a large hospital network and seeks to list on BSE and NSE through a bookbuilding process. Market capitalization cited is ₹77,605.68 crore. The registrar for the IPO is to be announced; lead managers are to be announced.
IPO Details: Price Band, Lot Size, Dates, And Quotas
Price band: ₹560 to ₹590 per share. Lot size: 25 shares. Issue size: 15,72,07,054 shares (up to ₹9,275 crore). Open date: 29 Jul 2026. Close date: 31 Jul 2026. Listing date: Wed, 5 Aug 2026. Exchanges: BSE, NSE. Fresh issue: 13,55,93,220 shares (up to ₹8,000 crore). OFS: 2,16,13,834 shares (up to ₹1,275 crore). Face value: ₹2 per share. QIB quota: Not less than 75% of Net Offer. NII quota: Not more than 15% of Net Offer. Retail quota: Not more than 10% of Net Offer. Registrar: To be announced. Lead Manager: To be announced. Market Cap: ₹77,605.68 Cr.
Retail, NII, and QIB subscription data are not available yet, reflecting the early stage of demand discovery for this large issue.
GMP Analysis: What It Means For Listing Gains
The current GMP is ₹15, which translates to roughly a 2.54% premium above the upper end of the price band on listing. This signals mild demand and suggests a potential, but not guaranteed, listing gain. Investors should treat GMP as one data point in a broader decision framework, alongside fundamentals, leverage, and price discovery during the IPO window.
Financial Snapshot: Revenue, Profit, Debt
Below is the financial snapshot from the RHP (two-year data):
| Period | Revenue | PAT | Net Worth | Borrowings |
|---|---|---|---|---|
| 31 Mar 2026 | ₹10,520.52 Cr | ₹916.52 Cr | ₹8,440.92 Cr | ₹10,553.43 Cr |
| 31 Mar 2025 | ₹8,362.79 Cr | ₹1,081.67 Cr | ₹5,865.66 Cr | ₹4,766.83 Cr |
Key takeaways from the numbers: Revenue growth YoY stands at +25.8%, while PAT shows a YoY decline of -15.3%. Net worth has risen meaningfully across the two-year window, but borrowings have more than doubled in the latest year, signaling rising leverage as the company funds its expansion. This debt tier is a meaningful variable for investors to monitor against cash flow visibility and earnings quality as the listing approaches.
Valuation &Amp Risks: Is ₹560-₹590 Fair?
With a large hospital network, strong revenue momentum, and a high scale, investors will weigh the price band against the imperative to see sustained profitability and debt management. The big borrowings (₹10,553.43 Cr in 2026) versus a net worth of ₹8,440.92 Cr raise questions about interest costs and debt servicing in a potentially uncertain macro backdrop. The PAT decline further adds to near-term earnings risk, even as the top-line growth remains a positive sign. The valuation must be judged against eventual earnings power, cash flows, and the ability to sustain capex without compromising balance-sheet health. The absence of finalized registrar and lead managers adds some execution risk to near-term price discovery.
Allotment Timeline &Amp Listing Day Expectations
The IPO opens on 29 July 2026 and closes on 31 July 2026. Listing is scheduled for 5 August 2026 (Wednesday) on BSE and NSE. Final registrar/lead manager details are pending, which means keep an eye on the exchange filing and issuer communications for the precise allotment timeline and any updates to the bookbuilding process. Retail participation will hinge on demand across categories and the eventual price discovery within the ₹560-₹590 band.
How To Apply: UPI/ASBA Process
To participate in the Manipal Health Enterprises IPO, use a standard IPO bid through your broker. You can apply via ASBA (Application Supported by Blocked Amount) or UPI-based bidding, depending on platform options and regulatory provisions. Here are practical steps:
- Log in to your Swastika Investmart trading account and navigate to the IPO portal.
- Enter bid quantity in multiples of 25 shares (the lot size) and select the price within ₹560-₹590 that fits your strategy.
- Choose ASBA or UPI as the payment method and confirm your bid. If you choose ASBA, your bank will block the bid amount until allotment; with UPI, payment is processed through the chosen method per platform flow.
- Await allotment results. If allotted, funds are debited; if not, blocked funds are released or refunds are processed as per exchange rules.
- For deeper, AI-assisted insights during decision-making, consider Swastika's Sarthi AI stock assistant: Swastika's Sarthi AI stock assistant.
Frequently Asked Questions
Is Manipal Health Enterprises IPO worth applying for at ₹560-₹590?
The decision hinges on your risk tolerance and how you weigh the debt load and profitability trajectory. While revenue grew, PAT fell YoY and borrowings surged, which adds risk to the valuation at the top of the band.
What does the GMP of ₹15 imply for listing gains?
GMP of ₹15 indicates a modest listing premium around 2.5%, suggesting mild demand but no guarantee of gains on listing day.
What are the retail allotment odds for this IPO?
Retail quota is capped at 10% of Net Offer, and Retail subscription data is not available yet; the final allotment depends on overall demand across all categories.
What are the key risks of investing in Manipal Health Enterprises IPO?
Key risks include high borrowings (₹10,553.43 Cr in 2026), PAT YoY decline (-15.3%), and a large issue size that may challenge price discovery if demand wanes.
How do I apply for Manipal Health Enterprises IPO using UPI/ASBA?
Use your broker’s IPO portal to submit a bid. You can select ASBA or UPI-based payment, confirm, and wait for allotment results. Refunds or unblocked funds occur after allotment according to results.
Conclusion
The Manipal Health Enterprises IPO is a large, debt-funded expansion bet with strong top-line momentum but a clear near-term earnings hurdle. For most retail investors, the combination of high leverage and a PAT slide in a high-ticket issue calls for caution – unless you have a defined post-listing plan and a high risk tolerance. Monitor price discovery, the final registrar/lead manager details, and subscription mix before committing meaningful money.
Decision: watchlist for most, with a cautious apply only if you have a strict budget and a long-term horizon. The reason: the debt load and earnings trajectory warrant more clarity before committing to a large allocation at the top end of the band.
.avif)
.avif)
.avif)
